Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2,Condition 3
2358,"Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46.",glomerular filtration trait,,RS:0000681,SD,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.3,,0.0106,0.03,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,GFR by inulin method,stz,154,days,streptozotocin (60 mg/kg) then insulin,99911,streptozotocin (60 mg/kg) ,insulin,
2358,"Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46.",glomerular filtration trait,,RS:0000681,SD,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.29,,0.0071,0.02,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,GFR by inulin method,stz,154,days,streptozotocin (60 mg/kg) then insulin then Moexipril (30-35 mg/kg/d) (for 112 days),99912,streptozotocin (60 mg/kg) ,insulin,Moexipril (30-35 mg/kg/d) (for 112 days)
2358,"Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46.",glomerular filtration trait,,RS:0000681,SD,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.3,,0.0071,0.02,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,GFR by inulin method,,,days,control condition,99913,control condition,,
2358,"Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46.",glomerular filtration trait,,RS:0000681,SD,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.29,,0.0035,0.01,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,GFR by inulin method,stz,224,days,streptozotocin (60 mg/kg) then insulin,99932,streptozotocin (60 mg/kg) ,insulin,
2358,"Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46.",glomerular filtration trait,,RS:0000681,SD,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.29,,0.0071,0.02,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,GFR by inulin method,stz,224,days,streptozotocin (60 mg/kg) then insulin then Moexipril (30-35 mg/kg/d) (for 112 days),99933,streptozotocin (60 mg/kg) ,insulin,Moexipril (30-35 mg/kg/d) (for 112 days)
2358,"Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46.",glomerular filtration trait,,RS:0000681,SD,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.29,,0.0035,0.01,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,GFR by inulin method,,,days,control condition,99934,control condition,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",glomerular filtration trait,,RS:0003240,MWF/ZtmRrrc,male,126 days,7,,CMO:0002943,renal filtration fraction,,,,0.19,,0.0227,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,control condition,100943,control condition,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",glomerular filtration trait,,RS:0003240,MWF/ZtmRrrc,male,126 days,8,,CMO:0002943,renal filtration fraction,,,,0.21,,0.0212,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,enalapril (50 mg/l) (for 60 days),100944,enalapril (50 mg/l) (for 60 days),,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",glomerular filtration trait,,RS:0003240,MWF/ZtmRrrc,male,246 days,8,,CMO:0002943,renal filtration fraction,,,,0.27,,0.0141,0.04,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,control condition,100945,control condition,,
2541,"Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9.",glomerular filtration trait,,RS:0003240,MWF/ZtmRrrc,male,246 days,6,,CMO:0002943,renal filtration fraction,,,,0.3,,0.0163,0.04,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,enalapril (50 mg/l) (for 182 days),100946,enalapril (50 mg/l) (for 182 days),,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.32,,0.02,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100604,puromycin aminonucleoside (50 mg/kg) ,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.32,,0.01,0.03,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours),100605,puromycin aminonucleoside (50 mg/kg) ,saralasin (0.3 mg/kg/hr) (for 0.5 hours),
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.29,,0.02,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100606,puromycin aminonucleoside (50 mg/kg) ,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.28,,0.03,0.09,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours),100607,puromycin aminonucleoside (50 mg/kg) ,0.9% sodium chloride solution (for 0.5 hours),
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.26,,0.01,0.03,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100472,0.9% sodium chloride solution (3 ml) ,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,7,,CMO:0002943,renal filtration fraction,,,,0.09,,0.004,0.0106,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100473,puromycin aminonucleoside (50 mg/kg) ,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002943,renal filtration fraction,,,,0.09,,0.01,0.0224,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100474,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.26,,0.01,0.0283,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100475,0.9% sodium chloride solution (3 ml) ,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.34,,0.02,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100476,puromycin aminonucleoside (50 mg/kg) ,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.28,,0.01,0.0283,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100477,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.32,,0.03,0.09,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100478,0.9% sodium chloride solution (3 ml) ,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.27,,0.01,0.0283,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100479,puromycin aminonucleoside (50 mg/kg) ,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.28,,0.01,0.03,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100480,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,
3138,"Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206.",glomerular filtration trait,,RS:0004778,MWF/Ztm,male,147 days to 112 days,8,,CMO:0002943,renal filtration fraction,,,,0.35,,0.0177,0.05,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,arterial catheter implantation and controlled hemorrhage,109246,arterial catheter implantation and controlled hemorrhage,,
3138,"Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206.",glomerular filtration trait,,RS:0004778,MWF/Ztm,male,147 days to 126 days,8,,CMO:0002943,renal filtration fraction,,,,0.32,,0.0212,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,arterial catheter implantation and controlled hemorrhage,109247,arterial catheter implantation and controlled hemorrhage,,